首页> 美国卫生研究院文献>BMC Infectious Diseases >Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract
【2h】

Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract

机译:益生菌唾液链球菌24SMB和口腔链球菌89a干扰上呼吸道病原体的生物膜形成

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundInfections of the ears, paranasal sinuses, nose and throat are very common and represent a serious issue for the healthcare system. Bacterial biofilms have been linked to upper respiratory tract infections and antibiotic resistance, raising serious concerns regarding the therapeutic management of such infections. In this context, novel strategies able to fight biofilms may be therapeutically beneficial and offer a valid alternative to conventional antimicrobials. Biofilms consist of mixed microbial communities, which interact with other species in the surroundings and communicate through signaling molecules. These interactions may result in antagonistic effects, which can be exploited in the fight against infections in a sort of “bacteria therapy”. Streptococcus salivarius and Streptococcus oralis are α-hemolytic streptococci isolated from the human pharynx of healthy individuals. Several studies on otitis-prone children demonstrated that their intranasal administration is safe and well tolerated and is able to reduce the risk of acute otitis media. The aim of this research is to assess S. salivarius 24SMB and S. oralis 89a for the ability to interfere with biofilm of typical upper respiratory tract pathogens.
机译:背景技术耳朵,鼻旁窦,鼻子和喉咙的感染非常普遍,对医疗保健系统来说是一个严重的问题。细菌生物膜已经与上呼吸道感染和抗生素耐药性相关,引起了对这种感染的治疗管理的严重关注。在这种情况下,能够对抗生物膜的新颖策略可能在治疗上有益,并提供了常规抗菌剂的有效替代品。生物膜由混合的微生物群落组成,这些微生物群落与周围的其他物种相互作用并通过信号分子进行通讯。这些相互作用可能导致拮抗作用,可以在某种“细菌疗法”中用于对抗感染。唾液链球菌和口腔链球菌是从健康个体的人咽分离出的α-溶血性链球菌。对易患中耳炎的儿童的多项研究表明,鼻内给药是安全且耐受性良好的,能够降低急性中耳炎的风险。这项研究的目的是评估唾液链球菌24SMB和口腔链球菌89a干扰典型上呼吸道病原体生物膜的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号